Article
A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome.
International journal of cancer - 20 Jan 2000
Blaszyk H, Hartmann A, Cunningham J M, Schaid D, Wold L E, Kovach J S, Sommer S S
Abstract excerpt
Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.